Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...

Experts discuss the current status of neoadjuvant ADC therapies, eligibility criteria, and future treatment pathways for high-risk patients.

Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.

DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals (JAZZ) plc today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...